Ashley EA, Niebauer J. Cardiology explained. Remedica Copyright © 2004, Remedica.: London; 2004.

Tackling G, Borhade MB. Hypertensive Heart Disease, in StatPearls. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL); 2023. Ineligible companies. Disclosure: Mahesh Borhade declares no relevant financial relationships with ineligible companies.

Gazewood JD, Turner PL. Heart failure with preserved ejection fraction: diagnosis and management. Am Fam Physician. 2017;96(9):582–8.

PubMed  Google Scholar 

Chobanian AV, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–71.

Article  CAS  PubMed  Google Scholar 

Levy D, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.

Article  CAS  PubMed  Google Scholar 

Vasan RS, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.

Article  CAS  PubMed  Google Scholar 

Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–1032.

PubMed  Google Scholar 

Verdecchia P, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38(7):1829–35.

Article  CAS  PubMed  Google Scholar 

Levy D, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90(4):1786–93.

Article  CAS  PubMed  Google Scholar 

Devereux RB, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110(11):1456–62.

Article  CAS  PubMed  Google Scholar 

Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Oxford: Oxford University Press; 1992.

Book  Google Scholar 

Klingbeil AU, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41–6.

Article  PubMed  Google Scholar 

Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21(5):500–8.

Article  PubMed  Google Scholar 

Massie BM, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.

Article  CAS  PubMed  Google Scholar 

Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

Article  CAS  PubMed  Google Scholar 

Hernandez AF, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53(2):184–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.

Article  CAS  PubMed  Google Scholar 

Solomon SD, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.

Article  CAS  PubMed  Google Scholar 

Lund LH, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230–9.

Article  CAS  PubMed  Google Scholar 

Butler J, Anker SD, Packer M. Redefining heart failure with a reduced ejection fraction. JAMA. 2019;322(18):1761–2.

Article  PubMed  Google Scholar 

Pascual-Figal DA, et al. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol. 2017;240:265–70.

Article  PubMed  Google Scholar 

Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71.

Article  PubMed  Google Scholar 

van Heerebeek L, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830–9.

Article  PubMed  Google Scholar 

Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

Article  CAS  PubMed  Google Scholar 

Pandey AK, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44(37):3640–51.

Article  CAS  PubMed  Google Scholar